The PS19 mouse model harbors the T34 isoform of microtubule-associated protein tau with one N-terminal insert and four microtubule binding repeats (1N4R) encoding the human P301S mutation, all driven by the mouse prion protein promoter. These mice are useful in studying neurofibrillary tangles, neurodegenerative tauopathy and Alzheimer's disease.
Virginia M Lee, University of Pennsylvania
Genetic Background | Generation |
---|---|
?+N3F10
|
Allele Type |
---|
Transgenic (Inserted expressed sequence, Humanized sequence) |
Starting at:
$270.00 Domestic price for female 4-week |
348.51 Domestic price for breeder pair |
These PS19 transgenic mice (P301S Tg mice) express the P301S mutant form of human microtubule-associated protein tau (MAPT), under the direction of the mouse prion protein promoter (Prnp). The expression of the mutant human MAPT is five-fold higher than the expression of the endogenous mouse MAPT protein. Hyperphosphorylated, insoluble mutant human MAPT protein in the brain accumulates with age causing decreased microtubule binding/density. At three months of age, transgenic mice exhibit clasping and limb retraction when lifted by the tail, which progresses to limb weakness. By ten months of age the mice exhibit a hunched back and paralysis, followed by inability to feed. Transgenic mice have a median lifespan of approximately nine months with approximately 80% dying by 12 months. Histological analysis reveals neuron degeneration in hippocampus and ventricular dilatation (brain atrophy) by eight months of age, although significant neuron degeneration in the hippocampus occurs at approximately nine months of age. Neuron loss spreads to the amygdala, neocortex and entorhinal cortex by 12 months of age. Defective translocation of endoplasmic reticulum proteins in affected neurons is observed as early as three months of age. The onset of neurofibrillay tangle formation in the neocortex, amygdala, hippocampus, brain stem and spinal cord is five months of age. Transgenic mice display neuroinflammation with microglial activation and astrogliosis. The ultrastructure of the neurofibrillay tangle-like lesions detected is similar to that found in brain lesions of human Alzheimer's disease and tauopathy patients. Degradation of synaptic function is significant by six months of age. These mice cannot be bred to homozygosity as homozygous females do not mate.
The phenotype of PS19 transgenic mice described above is based on the published information available as of 2008. In 2012-2013, publications using PS19 mice on a B6C3F1 or B6C3 genetic background report attenuated formation of tau pathology (hyperphosphorylated tau inclusions prominent by 12 months of age, significant neuronal death after 12 months of age), as well as males developing tau pathology more consistently than females. It is not determined if these phenotype differences are observed for the PS19 colony at The Jackson Laboratory. To ensure genetically stability, we periodically refresh our colony onto the hybrid B6C3F1/J genetic background (Stock No. 100010). This was last performed March to November 2016.
As of October 2017, the Stock No. 008169 live colony is homozygous for the C57BL/6-derived functional Pde6b+ allele (the C3H-derived Pde6brd1 allele has been selectively removed). As of May 2019, the Stock No. 008169 live colony is homozygous for the Tlr4+ allele.
The P301S transgene was designed with the P301S mutant human microtubule-associated protein tau (MAPT*P301S) under the direction of the mouse prion protein promoter (Prnp). This transgene was injected into fertilized B6C3F1 mouse eggs. Transgenic founder animals were bred to B6C3F1/J or B6C3F1/Crl mice to establish founder line 19 (PS19). The resulting PS19 colony was maintained as hemizygotes on the B6C3F1 background before sending to The Jackson Laboratory Repository in 2008.
As of October 2017, the Stock No. 008169 live colony is homozygous for the C57BL/6-derived functional Pde6b+ allele (the C3H-derived Pde6brd1 allele has been selectively removed). As of May 2019, the Stock No. 008169 live colony is homozygous for the Tlr4+ allele.
Expressed Gene | MAPT, microtubule associated protein tau, human |
---|---|
Site of Expression |
Allele Name | transgene insertion PS19, Virginia M Y Lee |
---|---|
Allele Type | Transgenic (Inserted expressed sequence, Humanized sequence) |
Allele Synonym(s) | P301S tau (line PS19); PS19 Tg |
Gene Symbol and Name | Tg(Prnp-MAPT*P301S)PS19Vle, transgene insertion PS19, Virginia M Y Lee |
Gene Synonym(s) | |
Promoter | Prnp, prion protein, mouse, laboratory |
Expressed Gene | MAPT, microtubule associated protein tau, human |
Strain of Origin | (C57BL/6 x C3H)F1 |
Chromosome | 3 |
Molecular Note | The transgene construct contains the P301S mutant human microtubule-associated protein tau, MAPT, under the direction of the mouse prion protein, Prnp, promoter. The expression of the mutant human MAPT is 5-fold higher than the expression of the endogenous mouse Mapt protein. Transgene insertion occurred on Chr 3, causing a 249 Kb deletion. |
Mutations Made By | Virginia Lee, University of Pennsylvania |
When maintaining a live colony, these mice can be bred as hemizygotes. These mice cannot be bred to homozygosity as homozygous females do not mate.
When using the Tau P301S (PS19) mouse strain in a publication, please cite the originating article(s) and include JAX stock #008169 in your Materials and Methods section.
Service/Product | Description | Price |
---|---|---|
Hemizygous or Non carrier for Tg(Prnp-MAPT*P301S)PS19Vle |
Frozen Mouse Embryo | B6;C3-Tg(Prnp-MAPT*P301S)PS19Vle/J | $2595.00 |
Frozen Mouse Embryo | B6;C3-Tg(Prnp-MAPT*P301S)PS19Vle/J | $2595.00 |
Frozen Mouse Embryo | B6;C3-Tg(Prnp-MAPT*P301S)PS19Vle/J | $3373.50 |
Frozen Mouse Embryo | B6;C3-Tg(Prnp-MAPT*P301S)PS19Vle/J | $3373.50 |
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.
What information were you hoping to find through your search?
How easy was it to find what you were looking for?
We may wish to follow up with you. Enter your email if you are happy for us to connect and reachout to you with more questions.
Please Enter a Valid Email Address
Thank you for sharing your feedback! We are working on improving the JAX Mice search. Come back soon for exciting changes.